- Trial phase
- Phase 2
- Time to market
- SPY130 is in Phase 2 testing with combination data expected in Q3 2027. If successful, Phase 3 trials would follow, meaning potential approval is likely several years away, likely 2029 or later.
- Why 6/10
- The next hard catalyst for SPY130 is the SKYLINE Part B Phase 2 combination topline data, expected in Q3 2027 (roughly 8-10 months from today). This is a mid-stage readout on a major pipeline asset at a company with multiple programs, warranting a score of 6.
The next major catalyst for SPY130 is the SKYLINE Part B combination data expected in Q3 2027. Positive results would validate the combination strategy and could accelerate the program toward Phase 3. Negative or mixed data would raise questions about the additive benefit of combining anti-alpha4beta7 and anti-IL-23 antibodies. Interim updates or enrollment completion announcements could move the stock in the interim.
Price Chart
Executive Summary
SPY130 is a preclinical-to-Phase 2 combination therapy from Spyre Therapeutics (NASDAQ: SYRE), pairing two long-acting antibodies (anti-alpha4beta7 and anti-IL-23) for inflammatory bowel disease. All three monotherapy components (SPY001, SPY002, SPY003) hit their primary endpoints in Part A of the Phase 2 SKYLINE trial in 2026, clearing the path for the combination study. SPY130 is now being tested in Part B of SKYLINE, which is enrolling faster than expected with topline combination data anticipated in Q3 2027. Spyre has a strong cash position of $1.47B and broad institutional support, but the drug is still in mid-stage development with no near-term binary catalyst and the company faces significant cash burn and recent dilutive financing.
How It Works
SPY130 is a combination of two engineered antibodies given together as a single treatment. SPY001 blocks alpha4beta7, a protein on immune cells that helps them travel to the gut and cause inflammation. SPY003 blocks IL-23, a signaling protein that drives inflammatory responses. By hitting both targets at once, SPY130 aims to more completely control inflammation in inflammatory bowel disease (ulcerative colitis and Crohn's disease) than either antibody alone. The antibodies are engineered for a long half-life, meaning patients could receive them as a shot under the skin every 3 to 6 months instead of the frequent infusions required by current therapies.
Trial Status
SPY130 is being evaluated in Part B of the Phase 2 SKYLINE-UC trial (NCT07012395), a platform study in moderate-to-severe ulcerative colitis. The combination portion is enrolling faster than expected with an increased enrollment target. All three monotherapy components (SPY001, SPY002, SPY003) previously met their primary endpoints in Part A of the same trial. Topline combination data is expected in Q3 2027.
The Two-Sided Case
Upcoming Catalysts
- SKYLINE Part B combination topline data (including SPY130, SPY120, SPY230) expected Q3 2027
- Potential preclinical or translational data presentations at medical conferences (e.g., ECCO, DDW, UEGW)
- Enrollment completion updates for the SKYLINE Part B trial
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Spyre Therapeutics, Inc. PRESS-RELEASE SYRE ·Originating report